CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

NCT04021082 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision to not initiate the trial

Conditions

Peripheral T-Cell Lymphoma (PTCL NOS)
Nodal Lymphomas of T Follicular Helper (TFH)
Follicular T-cell Lymphoma (FTCL)
AITL
ALCL
HSTCL
EATL I,II
MEITL, EATL Type II
Nasal Lymphoma

Interventions

DRUG: Cerdulatinib

Sponsor

Portola Pharmaceuticals